Cholinesterase inhibitors (ChEIs) are the only currently available medications that may modestly decrease the cognitive impairment in patients with mild to moderate Alzheimer’s disease (AD) [1–3]. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.